J. J. Body, MD; N. Demeester-Mirkine, MD; J. Corvilain, MD
Because the long-feared carcinogenic and genetic hazards of radioactive iodine (131I) have been refuted (1), many authors now consider this therapy the treatment of choice for patients with toxic multinodular goiter and for most patients with Graves disease. Moreover, the use of ablative doses was recently recommended to correct hyperthyroidism rapidly and to cause hypothyroidism predictably, contrasting with the delayed and unpredictable occurrence of hypothyroidism after conventional 131I treatment (2). Intrathyroidal C cells do not trap radioactive iodine but could be damaged indirectly due to their contiguity to follicular cells, as suggested by some reports (3) of an antitumoral effect
Body JJ, Demeester-Mirkine N, Corvilain J. Calcitonin Deficiency after Radioactive Iodine Treatment. Ann Intern Med. ;109:590–591. doi: 10.7326/0003-4819-109-7-590
Download citation file:
Published: Ann Intern Med. 1988;109(7):590-591.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use